drug
DEFERASIROX
Marketedupdated 3mo agoby Reddy US Therapeutics Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5all catalysts(7)
approval · 7
Jan 26, 2016
approval
DEFERASIROX — FDA approval
DEFERASIROX
→
Oct 21, 2025
approval
DEFERASIROX — FDA approval
DEFERASIROX
→
Oct 21, 2025
approval
DEFERASIROX — FDA approval
DEFERASIROX
→
Oct 21, 2025
approval
DEFERASIROX — FDA approval
DEFERASIROX
→
Oct 21, 2025
approval
DEFERASIROX — FDA approval
DEFERASIROX
→
Oct 21, 2025
approval
DEFERASIROX — FDA approval
DEFERASIROX
→
Oct 21, 2025
approval
DEFERASIROX — FDA approval
DEFERASIROX
→
Trials studying DEFERASIROX
- phase2Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents
- phase2Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)
- phase2Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload
- phase2Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
- phase4Pilot Study for Patients With Poor Response to Deferasirox
- phase2The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 21, 2034
~8.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Nov 21, 2034compositionUS 9283209
- Nov 21, 2034compositionUS 9283209
- Nov 21, 2034compositionUS 9283209
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that